Cahill Financial Advisors Inc. Has $236,000 Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Cahill Financial Advisors Inc. reduced its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 12.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,620 shares of the financial services provider’s stock after selling 229 shares during the period. Cahill Financial Advisors Inc.’s holdings in iShares Biotechnology ETF were worth $236,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Blue Fin Capital Inc. lifted its holdings in shares of iShares Biotechnology ETF by 0.7% during the 2nd quarter. Blue Fin Capital Inc. now owns 10,516 shares of the financial services provider’s stock worth $1,443,000 after acquiring an additional 74 shares during the last quarter. Security National Bank of SO Dak grew its position in iShares Biotechnology ETF by 0.7% in the 2nd quarter. Security National Bank of SO Dak now owns 10,461 shares of the financial services provider’s stock worth $1,436,000 after purchasing an additional 75 shares during the period. SPC Financial Inc. lifted its position in iShares Biotechnology ETF by 2.4% during the third quarter. SPC Financial Inc. now owns 3,265 shares of the financial services provider’s stock valued at $475,000 after purchasing an additional 75 shares in the last quarter. Werba Rubin Papier Wealth Management grew its position in shares of iShares Biotechnology ETF by 2.7% during the third quarter. Werba Rubin Papier Wealth Management now owns 2,918 shares of the financial services provider’s stock valued at $425,000 after purchasing an additional 76 shares in the last quarter. Finally, Main Street Financial Solutions LLC raised its position in iShares Biotechnology ETF by 1.0% during the second quarter. Main Street Financial Solutions LLC now owns 8,002 shares of the financial services provider’s stock valued at $1,098,000 after purchasing an additional 82 shares during the period. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 1.4 %

Shares of NASDAQ IBB opened at $137.96 on Monday. The stock’s fifty day simple moving average is $143.43 and its two-hundred day simple moving average is $141.87. iShares Biotechnology ETF has a 12-month low of $117.28 and a 12-month high of $150.57.

iShares Biotechnology ETF Announces Dividend

The business also recently announced a dividend, which was paid on Monday, September 30th. Shareholders of record on Wednesday, September 25th were issued a $0.2005 dividend. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.